Across TCGA pan-cancer cohorts, AP3M1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated AP3M1 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher AP3M1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated AP3M1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and PDAC show a favorable association.

LSCC, UCEC, and LUAD are the cancer types where AP3M1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	All	0.883	0.985	.004	23	view →
UCEC	DFS	Median	All	0.980	0.828	.004	20	view →
LUAD	OS	Median	II,III,IV	0.862	1.000	.004	4	view →
PDAC	DFS	Tertile	II,III,IV	0.402	0.176	.013	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: AP3M1 tumor-vs-normal RNA expression · all AP3M1 data types